Innovative BioDefense Announces Partnership With Picketts Health to Sell Zylast
Innovative BioDefense Inc. (IBD), manufacturer of the Zylast line of broad-spectrum, persistent antimicrobial products, announces an exclusive relationship with Australian-based Picketts Health, to provide a modification of their proprietary lotion and antiseptic sanitizer for use in Picketts Health's patented Orbel hand sanitizer applicator. IBD has delivered a pilot production batch and is currently fulfilling Picketts' first orders. Picketts Health has committed to the purchase of $1.5 million in product from IBD during the first year, with a projection to increase to $4 million in the second year.
The Orbel was designed to increase hand-hygiene compliance and help prevent the spread of bacteria and viruses. Portable, with single-handed activation of a regulated dose, the Orbel's multi-directional balls evenly facilitate distribution to all parts of the hands for increased protection.
The Zylast line of antimicrobial products is all natural, water-based and triclosan-free. Zylast has shown to kill 99.99 percent of most disease-causing germs in 15 seconds and is persistent for six hours. Independent studies have shown Zylast to be effective against a broad spectrum of germs that includes 25 bacteria such as E. coli, S. pneumoniae, meningitis, methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE), viruses such as rhinovirus, norovirus, H1N1, HIV and herpes, as well as molds and fungi.Â
"We are pleased Picketts Health has taken an important step toward solving the issue of compliance with the introduction of the Orbel," says Dr. Colette Cozean, chief executive officer for Innovative BioDefense Inc. "Their choice in bringing Zylast in as the formulary shows their commitment to providing the premier antimicrobial solution." The first markets Picketts Health plans to target are the United Kingdom, South Africa, Australia and China. Zylast is protected by trademarks and patents pending in many countries worldwide.
Source: Innovative BioDefense Inc.
Tackling Health Care-Associated Infections: SHEA’s Bold 10-Year Research Plan to Save Lives
December 12th 2024Discover SHEA's visionary 10-year plan to reduce HAIs by advancing infection prevention strategies, understanding transmission, and improving diagnostic practices for better patient outcomes.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
The Importance of Hand Hygiene in Clostridioides difficile Reduction
November 18th 2024Clostridioides difficile infections burden US healthcare. Electronic Hand Hygiene Monitoring (EHHMS) systems remind for soap and water. This study evaluates EHHMS effectiveness by comparing C difficile cases in 10 hospitals with CMS data, linking EHHMS use to reduced cases.
